SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

11 Aug 2022 Evaluate
The revenue slipped marginally during the June 2022 quarter. A decline of about Rs. 27869.20 millions was observed as compared to Rs. 28937.50 millions during the corresponding quarter last year.Profit after Tax for the quarter ended June 2022 saw a decline of -43.20% from Rs. 2150.70 millions to Rs. 1221.60  millions.A decline of 2809.70 millions was observed in the OP in the quarter ended June 2022 from 4547.60 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 27869.20 28937.50 -3.69 27869.20 28937.50 -3.69 112871.40 158236.80 -28.67
Other Income 387.10 439.50 -11.92 387.10 439.50 -11.92 6709.90 5898.60 13.75
PBIDT 2809.70 4547.60 -38.22 2809.70 4547.60 -38.22 21443.90 47096.90 -54.47
Interest 78.50 50.60 55.14 78.50 50.60 55.14 169.40 286.80 -40.93
PBDT 2731.20 4497.00 -39.27 2731.20 4497.00 -39.27 20527.40 46810.10 -56.15
Depreciation 1030.50 1146.50 -10.12 1030.50 1146.50 -10.12 4152.60 4880.00 -14.91
PBT 1700.70 3350.50 -49.24 1700.70 3350.50 -49.24 16374.80 41930.10 -60.95
TAX 479.10 1199.80 -60.07 479.10 1199.80 -60.07 1827.70 10801.00 -83.08
Deferred Tax -89.90 -234.60 -61.68 -89.90 -234.60 -61.68 -1969.30 367.60 -635.72
PAT 1221.60 2150.70 -43.20 1221.60 2150.70 -43.20 14547.10 31129.10 -53.27
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 10.08 15.72 -35.85 10.08 15.72 -35.85 19.00 29.76 -36.17

Aurobindo Pharma Share Price

1377.65 -8.00 (-0.58%)
20-Apr-2026 11:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.45
Dr. Reddys Lab 1235.50
Cipla 1236.00
Zydus Lifesciences 939.75
Lupin 2332.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×